Mortality excess in individuals with elevated IgA anti-transglutaminase antibodies: the KORA/MONICA Augsburg cohort study 1989-1998.
about
Evolutionary and functional analysis of celiac risk loci reveals SH2B3 as a protective factor against bacterial infectionThe diagnosis and treatment of celiac diseaseDiagnosis of celiac disease.Screening for celiac disease in the general population and in high-risk groupsMalignancy and mortality in a population-based cohort of patients with coeliac disease or "gluten sensitivity"Identification of Non-HLA Genes Associated with Celiac Disease and Country-Specific Differences in a Large, International Pediatric CohortBarriers impeding serologic screening for celiac disease in clinically high-prevalence populations.Symptoms and signs in individuals with serology positive for celiac disease but normal mucosa.Anti-Apolipoprotein A-1 IgG Predict All-Cause Mortality and Are Associated with Fc Receptor-Like 3 Polymorphisms.Celiac disease.Predictors of family risk for celiac disease: a population-based studyMucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free dietCeliac disease and pediatric type 1 diabetes: diagnostic and treatment dilemmas.Morbidity and mortality among older individuals with undiagnosed celiac disease.Increased prevalence and mortality in undiagnosed celiac disease.Screening for celiac disease in a North American population: sequential serology and gastrointestinal symptomsScreening for celiac disease in average-risk and high-risk populations.Clinical utility of serologic testing for celiac disease in asymptomatic patients: an evidence-based analysis.The prevalence of celiac disease in children and adolescents in Germany.Patients with celiac disease are not followed up adequately.Increased mortality among men aged 50 years old or above with elevated IgA anti-transglutaminase antibodies: NHANES III.Roles of transglutaminases in cardiac and vascular diseases.Decreased prevalence of celiac disease among Brazilian elderly.Autoantibodies in celiac disease.Does celiac disease influence survival in lymphoproliferative malignancy?Meta-analysis: coeliac disease and the risk of all-cause mortality, any malignancy and lymphoid malignancy.Are we diagnosing too many people with coeliac disease?Long-term care for patients with coeliac disease in the UK: a review of the literature and future directions.Population screening for coeliac disease in primary care by district nurses using a rapid antibody test: diagnostic accuracy and feasibility study.Incidence of lymphoproliferative disorders in patients with celiac disease.Younger age at diagnosis predisposes to mucosal recovery in celiac disease on a gluten-free diet: A meta-analysis.The prevalence of celiac disease in Europe: results of a centralized, international mass screening project.Mortality in coeliac disease: a population-based cohort study from a single centre in Southern Derbyshire, UK.A Cautionary Tale of Purity, Labeling and Product Literacy in the Gluten-Free MarketPrognosis of unrecognized coeliac disease as regards mortality: A population-based cohort studyThe long-term risk of malignancy following a diagnosis of coeliac disease or dermatitis herpetiformis: a cohort studyCauses of Death in People With Celiac Disease Spanning the Pre- and Post-Serology Era: A Population-Based Cohort Study From Derby, UKNo difference in mortality in undetected coeliac disease compared with the general population: a UK cohort study
P2860
Q24632121-9793D5B7-70C4-4714-848D-BC470400A793Q26865802-91E4C72C-A233-45C9-83B4-29D88DDBEF60Q27691443-BAE94567-969D-4DC3-B52D-AFB91DBE5319Q28085750-19515B9E-6964-44DC-909F-AAC62825F074Q28282112-89204F02-14FA-4659-A086-2A5D5049DB25Q30277090-4A6C42C0-CB31-4FA5-8F52-D0A11E533ACEQ31152322-A53C9C3F-D54C-40F3-AD84-0FDE6EA06FE1Q33485528-7D7BC859-CDC3-4CA4-941B-C1E852AC888EQ33573479-42E77B76-E978-4BD0-AAAC-1796ED9E9BFDQ33696823-1783C9F7-9B7E-4932-9DDC-9EACEC1800A6Q33696829-4D931035-327C-421F-AB6A-C6407BF6C9E3Q33895514-AF415C32-2752-4A9D-AB98-5C02038D9BDEQ34002003-C7A0B0C0-661B-4F63-AFCE-5DADF5A52CA4Q34091853-F6723251-954E-43B2-A5EF-CE41F31FFEC0Q34606436-BF44BDB0-91F2-4C5B-A60A-B32E53A653F5Q35089737-F2815BFB-B0CB-41B7-B343-D63865F68E43Q35688589-BBF3FBC1-4F71-4EC4-9CC9-5B9422202A04Q36040109-687A9A70-389B-4C20-8921-C0144B3C2E1FQ36062726-0B163234-5B0E-4BB7-BD20-BE37F158F946Q36110318-A4900AE3-E7BE-4EB7-98A7-CE8DE819FB8DQ36181407-08A46DF4-0EF1-4B68-BA92-948AFC282331Q36664166-5FE9EFB4-83E1-41BC-A626-10092DD9B296Q36731178-E36C2B82-E8A5-4A69-A55F-C7E7461FFFC2Q37051224-145626C4-0EF7-4DA0-961C-F9AED1EC4FFFQ37457894-28E09BD7-6A9A-490D-AB49-4A7C5BDE65B2Q37975303-E834466C-8A2D-4808-923C-C113F2C21AB6Q38020258-FBE54640-8026-4518-9F8C-ABF4C2FE05AEQ38838366-5FAC3648-F6B1-483D-8E73-3AB837E223D8Q41832081-A419A916-4094-4718-92AE-415933C2D670Q44322440-15CFB338-8795-4B08-8529-1DB5D06E2F53Q45710852-954AE160-2171-4D48-93EA-EF82777DB276Q53164308-DABB1227-9776-4995-A1B3-0FD11EFD1FC6Q53281337-1295E259-AD5E-48A1-8AC5-A29BD886CD16Q58198427-54ED28D4-4799-45F6-9E63-AB6AD898A933Q58270345-2546C9EB-37DB-46CE-AE93-35497CD6F9B9Q58376286-00B8F0B4-8251-4F2A-AAAC-061283B0597AQ58376294-562C1F80-4297-4B11-B146-F39123AB4872Q58376297-3E7895A4-F5D8-49D9-B09C-C8B234A2FA2B
P2860
Mortality excess in individuals with elevated IgA anti-transglutaminase antibodies: the KORA/MONICA Augsburg cohort study 1989-1998.
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
Mortality excess in individual ...... gsburg cohort study 1989-1998.
@ast
Mortality excess in individual ...... gsburg cohort study 1989-1998.
@en
Mortality excess in individual ...... gsburg cohort study 1989-1998.
@nl
type
label
Mortality excess in individual ...... gsburg cohort study 1989-1998.
@ast
Mortality excess in individual ...... gsburg cohort study 1989-1998.
@en
Mortality excess in individual ...... gsburg cohort study 1989-1998.
@nl
prefLabel
Mortality excess in individual ...... gsburg cohort study 1989-1998.
@ast
Mortality excess in individual ...... gsburg cohort study 1989-1998.
@en
Mortality excess in individual ...... gsburg cohort study 1989-1998.
@nl
P2093
P1476
Mortality excess in individual ...... gsburg cohort study 1989-1998.
@en
P2093
Andrea Schneider
Detlef Schuppan
Enzo Bravi
Hannelore Löwel
Heinz-Erich Wichmann
Marie-Hélène Metzger
Markku Mäki
P2888
P304
P356
10.1007/S10654-006-9002-4
P577
2006-04-29T00:00:00Z
P6179
1048930426